Merrimack is committed to the fight against cancer. We are a science-driven community seeking to understand the complexity of the disease, engineer better solutions and deliver life-saving results for patients.

A Review in Science Signaling: Rerouting Cellular Traffic to Design Better Drugs - Understanding Cellular Signaling Networks with Systems Biology

Learn More

Learn More About Our Phase 2 Clinical Trial of MM-111 For HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach

Learn More

MM-141 blocks adaptation of PI3K/AKT/mTOR survival pathway

A recent manuscript shows that adaptive ErbB3 signaling is a key factor limiting the utility of anti-IGF-1R agents. MM-141, a bispecific tetravalent antibody, co-blocks IGF and heregulin-induced signaling and induces degradation of receptor complexes containing IGF-1R and ErbB3. MM-141 also potentiates mTOR inhibitors and taxanes, supporting its ongoing clinical development.

Learn More

Our Heroes

Merrimack is delighted to announce its alliance with the Pancreatic Cancer Action Network, an organization dedicated to advancing research, supporting patients and creating hope for those affected by pancreatic cancer. 

Learn More

Using Nanotechnology to Improve Treatment for Pancreatic Cancer

MM-398, an exploratory new medicine for pancreatic cancer, is founded on a technology that allows us to increase a tumor cell's  exposure to chemotherapy. Learn more about MM-398.

Learn More

Breaking down the science of systems biology

Professor Peter Sorger of Harvard Medical School discusses the science of systems biology and its potential impact on cancer care.

Learn More

New Insights in Cancer: A Novel Therapy with the Potential to Treat a Central Node in Cancer

MM-121 is a novel signaling inhibitor being developed by Merrimack and Sanofi Oncology across multiple cancer indications, including breast, lung and ovarian cancer. Our research suggests that MM-121’s target, HER3, could play a substantial role in the growth and survival of cancer. Learn more about MM-121 and its clinical program here.

Click here